Jefferies Reiterates Buy Rating on Nektar Therapeutics (NKTR)

Jefferies analyst Roger Song reiterated a Buy rating and $121.00 price target on Nektar Therapeutics (NASDAQ: NKTR).

The analyst comments "We caught up with mgmt. We see Ph2b achieved key goals - confirming good safety, matching efficacy vs. low dose Olumiant with potential to beat, learning protocol nuances, selecting Ph3 dosing, and supported high likelihood of first "clean/ efficacious biologic" for AA pts that could expand market opportunity by being used in 1L and even less severe pts vs. JAKi. We like set-up into next year long-term data from AD and AA which likely drive upside potential."

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $49.16 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Fiserv (FISV) PT Lowered to $60 at Freedom Broker